Literature DB >> 7534632

Bladder and kidney cancers.

M McCredie1.   

Abstract

The major factor contributing to the increase in incidence of both renal and urothelial cancers has been improved detection rates. To a considerable extent, this accounts for the difference between the trends in incidence and mortality since, on the whole, the efficacy of treatment has improved only slowly. In the case of renal parenchymal cancer, the true burden of disease is rising almost everywhere, probably reflecting changes in standard of living, perhaps chiefly diet, although there will be some contribution from smoking. Where the increase in bladder cancer is not artefactual, it can be attributed in large part to smoking and perhaps to increasing industrial exposure in some localities. Trends in incidence and, to a greater degree, mortality for urothelial cancer are likely to improve substantially with implementation of policies of prevention (reduction in smoking, improvements in industrial hygiene), earlier detection (eg with monoclonal antibodies) and treatment (immunotherapy). No such optimism can be held with respect to renal parenchymal cancer, which is set to become one of the major cancers of affluent societies unless its aetiology becomes known and can be addressed.

Entities:  

Mesh:

Year:  1994        PMID: 7534632

Source DB:  PubMed          Journal:  Cancer Surv        ISSN: 0261-2429


  9 in total

1.  Steal phenomenon in the lower limb: presentation of a case with osseous metastases secondary to renal cell carcinoma and review of the literature.

Authors:  Mohammed Asha; Husam Ibrahim; Abdalla Khidir Eisawi; Richard Orme; Andrew Houghton
Journal:  BMJ Case Rep       Date:  2009-03-24

2.  Value of MRI imaging prior to a kyphoplasty for osteoporotic insufficiency fractures.

Authors:  Ulrich Josef Albert Spiegl; R Beisse; S Hauck; A Grillhösl; V Bühren
Journal:  Eur Spine J       Date:  2009-06-06       Impact factor: 3.134

3.  Prognostic value of caveolin-1 in genitourinary cancer: a meta-analysis.

Authors:  Jia-Ming Liu; Si-Hang Cheng; Xiao-Xiao Liu; Chao Xia; Wei-Wen Wang; Xue-Lei Ma
Journal:  Int J Clin Exp Med       Date:  2015-11-15

4.  Second primary cancers following cancers of the kidney and prostate in New South Wales (Australia), 1972-91.

Authors:  M McCredie; G J Macfarlane; J Stewart; M Coates
Journal:  Cancer Causes Control       Date:  1996-05       Impact factor: 2.506

5.  Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma.

Authors:  Song Wu; Yong Wang; Liang Sun; Zhiling Zhang; Zhimao Jiang; Zike Qin; Hui Han; Zhuowei Liu; Xianxin Li; Aifa Tang; Yaoting Gui; Zhiming Cai; Fangjian Zhou
Journal:  BMC Cancer       Date:  2011-09-26       Impact factor: 4.430

6.  Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events.

Authors:  Xianxin Li; Jiahao Chen; Xueda Hu; Yi Huang; Zhizhong Li; Liang Zhou; Zhijian Tian; Hongyu Ma; Zhiyun Wu; Maoshan Chen; Zujing Han; Zhiyu Peng; Xiaokun Zhao; Chaozhao Liang; Yong Wang; Liang Sun; Jing Chen; Jun Zhao; Binghua Jiang; Huanming Yang; Yaoting Gui; Zhiming Cai; Xiuqing Zhang
Journal:  PLoS One       Date:  2011-07-25       Impact factor: 3.240

7.  Trends in the incidence and mortality of kidney cancer in Lithuania from 1993 to 2012.

Authors:  Aušvydas Patašius; Agnė Ulytė; Albertas Ulys; Giedrė Smailytė
Journal:  Acta Med Litu       Date:  2018

8.  Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?

Authors:  J M Bartlett; A D Watters; S A Ballantyne; J J Going; K M Grigor; T G Cooke
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

9.  Percutaneous needle biopsy for indeterminate renal masses: a national survey of UK consultant urologists.

Authors:  Azhar A Khan; Iqbal S Shergill; Sheila Quereshi; Manit Arya; Mohammed T Vandal; Sandeep S Gujral
Journal:  BMC Urol       Date:  2007-07-04       Impact factor: 2.264

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.